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ABSTRACT
Objective: To explore the optimal content and design
of a clinical trial of an end-of-life intervention for
advanced heart disease with patients, carers and
healthcare professionals.
Design: Qualitative interview and focus group study.
Setting: Community and hospital-based focus groups
and interviews.
Participants: Stable community-dwelling patients,
informal carers (PC, n=15) and primary and secondary
care based healthcare professionals (HCP, n=11).
Results: PC highlighted fragmentation of services and
difficulty in accessing specialist care as key barriers to
good care. They felt that time for discussion with HCP
was inadequate within current National Health Service
(NHS) healthcare systems. HCP highlighted uncertainty
of prognosis, explaining mortality risk to patients and
switching from curative to palliative approaches as key
challenges. Patient selection, nature of the intervention
and relevance of trial outcomes were identified by HCP
as key challenges in the design of a clinical trial.
Conclusions: PC and HCP expressed a number of
concerns relevant to the nature and content of an end-
of-life intervention for patients with advanced heart
disease. The findings of this study are being used to
support a phase II randomised clinical trial of Future
Care Planning in advanced heart disease.
INTRODUCTION
Patients with cancer have well-developed pal-
liative care services while patients with
advanced heart disease do not as highlighted
in two major reports by The Department of
Health in England and Wales1 and Scottish
Government Action Plan ‘Living and Dying
Well’.2 These documents promote the provi-
sion of care in the last year of life that is
person-centred regardless of diagnosis. The
recent National Health Service (NHS)
quality Improvement Scotland Clinical
Standards for Heart Disease recommend a
palliative care assessment in all forms of
advanced heart disease.3 Recent publications
relating to end-of-life (EOL) care in heart
disease have focused on congestive heart
Strengths and limitations of this study
▪ This qualitative interview study has provided a
360° perspective from patients, carers and
healthcare professionals on the content, nature
and mode of delivery of an intervention that
could be tested in a clinical trial and that could
impact on quality of life.
▪ The findings suggest that a randomised (early vs
delayed) protocol is broadly acceptable, that clin-
ical prognostic scores could be used to identify
eligible patients in the hospital setting, that care
needs should also be incorporated into the eligi-
bility criteria and that the intervention should
include components that address the current
gaps in high-quality holistic care (as identified by
patients and their carers).
▪ The relatively small number of patients and
healthcare professionals participating in the
study and the fact that all patients were stable in
a community setting may have impacted on the
findings.
▪ Engaging patients and carers in the rationale,
content and design of a randomised clinical trial
is challenging and requires careful design and
planning.
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failure (CHF) but coronary disease and valvular heart
disease commonly coexist in patients with CHF, so an
integrated approach to all end-stage heart diseases is
appropriate.
We recently explored ways of identifying patients who
are approaching EOL in an acute cardiology ward.
Using the Gold Standards Framework criteria and vali-
dated prognostic tools we demonstrated that most
patients with advanced heart failure4 and a lesser pro-
portion with acute coronary events5 have a very limited
prognosis despite optimal evidence-based care. Poor
prognosis is a marker of lower quality of life, increased
hospitalisation, multimorbidity6 and is an indirect
marker of increasing patient needs. There are well-
validated prognostic tools for patients with CHF7 and
acute coronary syndrome (ACS).8 Once a patient with a
poor prognosis is identiﬁed, this should ideally be fol-
lowed by an evidence-based intervention9–11 that could
improve quality of life for the patient and their family.
In keeping with palliative care models,12 this interven-
tion should be patient-focused and should address indi-
vidual needs. Ideally the intervention should integrate
patient preferences with clinical priorities using ‘shared
decision-making’.13 From these discussions, a Future
Care Plan (FCP) may be derived and written in terms
that the patient understands. The FCP should contain a
clinical plan of how to manage acute events of deterior-
ating health with mechanisms to inform out-of-hours ser-
vices and maintain continuity of care. The plan should
be reviewed regularly in the context of the patient’s
evolving multidimensional needs. Such an intervention
could be initiated by the patient’s cardiologist and deliv-
ered by a specialist heart disease nurse working in part-
nership with the primary care team and palliative care
specialists.
Trials of palliative care are recognised to be extremely
difﬁcult to design and implement.14 One previous ran-
domised trial suggested that routine palliative care in
addition to normal oncological care could improve
quality of life in people with lung cancer.12 A robust
phase II trial, as recommended by the Medical Research
Council in its guidance for complex interventions,15 is
needed as a ﬁrst step towards achieving a similar goal
for people with advanced heart disease.
The proposed study outlined here incorporates these
issues using a mixed methods, phase I and II trials, design
and is similar to methodologies used elsewhere to develop
complex palliative care interventions for non-cancer ill-
nesses.16 17 The proposed trial is novel in that it includes a
broad group of patients with CHF and ACS; it will assess
whether well-validated clinical prognostic tools can be
used to identify patients approaching EOL and will
develop a feasible care planning intervention. In addition
to assessing prognosis as a trigger, the study also seeks to
explore the interface between acute cardiology services,
primary care and specialist palliative care services.
Here we describe the ﬁndings of a qualitative interview
study using patient-carer focus groups (PCFG) and a
range of healthcare professionals (HCPs) to explore
ways in which a holistic intervention could be tested in a
randomised clinical trial setting.
METHODS
The basic design for a clinical trial outline was devel-
oped by the authors as part of a submission for research
funding using their background knowledge and experi-
ence and based on other trial designs of a similar
nature.16 17 This was approved by the funder and by the
local ethics committee on the understanding that the
design of the study could be modiﬁed following a con-
sultation/modelling phase which would involve focus
groups of patients and carers and one-to-one interviews
with a range of HCPs about the proposed trial design.
PCFG were then undertaken with the members of an
existing hospital-based heart failure patient-carer forum
(n=7) and a second focus group was undertaken in con-
junction with a local heart disease charity (n=8 partici-
pants) each lasting for 2 h. Discussions were facilitated
by an experienced qualitative researcher (GH) using a
set of questions, designed by the authors, addressing
their experiences with clinical care and the proposed
design of the randomised controlled trial (see online
supplementary appendix 1A). Various options associated
with the trial were presented and discussed with patients
and carers including eligibility criteria and whether the
control group should or should not receive EOL
intervention.
A separate series of one-to-one interviews were con-
ducted with a range of HCPs (total n=11, palliative care
consultant n=3, cardiology consultant n=3, heart failure
specialist nurse n=1, medicine of the elderly specialist
n=1, cardiology ward charge nurse n=1, general practi-
tioner n=1, district nurse n=1) by an experienced qualita-
tive researcher using a set of questions incorporating
themes related to clinical care, palliative care and clinical
trials design (see online supplementary appendix 1B).
Discussions regarding the proposed design of the trial
were initially broad and later in the interview focused
more on the eligibility criteria, types of patients that
should be included and whether an active control group
should be incorporated. Both types of participants were
provided with a sample ‘FCP’ and a ﬂow diagram of the
basic proposed design of the clinical trial prior to the
interviews. These documents acted as focal points for
discussion. Interviews and focus groups were transcribed
and analysed using NVivo to extract themes related to
the rationale and design of a clinical trial of a holistic
intervention addressing a range of issues related to EOL
care.
The ﬁndings from these interviews and focus group
discussions were then used to modify the proposed
design of a trial of an intervention to support patients
with advanced heart disease identiﬁed as being at high
risk of death within the next 12 months. All participants
gave signed informed consent.
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RESULTS
Patient’s and carer’s views
Care for cardiac patients
PCFG highlighted increasing difﬁculties associated with
multiple care providers working in apparent isolation as
a major difﬁculty in ensuring holistic care. From a PCFG
perspective, care appears increasingly fragmented and ill
designed to manage the needs of frail, elderly patients
with multiple chronic conditions.
PCFG also identiﬁed the variation in access to special-
ist services as a key problem in providing holistic,
patient-centred care. This applied in particular to heart
failure nurse care where many services adhere to strict
eligibility criteria which include left ventricular systolic
dysfunction and recent hospital admission. Patients with
access to the heart failure specialist nurse service were
very appreciative of their support, but they expressed
concern that this service was not available to everyone
with heart failure and people with other types of
advanced heart conditions.
PCFG welcomed the idea of future or anticipatory
care planning, and appeared to recognise its value.
However, a minority felt that this could be a very difﬁcult
process to engage in, expressing views that it needs to be
carefully targeted and people should be able to choose,
without pressure, not to engage in the process (box 1).
PCFG highlighted the fact that some patients will
already be well informed about their condition and its
prognosis. However, it was also expressed that for those
who have less insight into their condition, doctors and
nurses should consider carefully how they will allay and
minimise fears about engaging in a process of Future
Care Planning.
Proposed trial of Future Care Planning
There was a general consensus in the PCFG that the
draft FCP planned for use in the trial (see online supple-
mentary appendix 2) was comprehensive and addressed
a number of concerns that families had about planning
for the future (box 2). However, one carer made the
point that a patient-centred anticipatory care plan must
be ﬂexible enough to accommodate those who are
acting on behalf of their loved one possibly using power
of attorney. Others suggested that it would be helpful to
ensure that all contact details of the medical teams
caring for a patient are included particularly for those
with multiple comorbidities. One patient also ques-
tioned the appropriateness of asking patients to identify
which potentially life-saving treatments they may or may
not want.
PCFG were supportive of the proposal for a clinical
trial and were satisﬁed with the basic design of the study.
Opposing views about eligibility criteria were expressed
by two participants in the same focus group with one
indicating that eligibility should include people with
advanced heart disease who were currently stable in the
community and not necessarily those recently admitted
to hospital. PCFG emphasised the need for families to
be well informed and prepared before being
approached about a trial testing the proposed interven-
tion. Eligibility for the trial using a threshold value for
estimated 12-month mortality was debated and discussed
Box 1 Patient-carer views: fragmentation of care
Once you get to our age, you discover that you’ve got more
than one problem, and you see the various consultants
who deal with the various problems, and they deal with you
like a car. They put the carburettor right, they put the radi-
ator right, but the holistic approach is missing (patient)
My condition is primarily a chronic lung condition but I
also have a heart condition. So I have two separate areas of
contact and they both know about each of the conditions
but they’re really only concentrating on the one they’re
dealing with, they soon forget, ‘oh, you’ve got a heart con-
dition, oh right!’ And it’s worrying particularly if you’re
being administered fairly serious medication and you’ve got
to remember that you’ve got all these conditions (patient)
Variation in access to specialist services
We have a very good rapport and have chats with her (The
Heart Failure Nurse). If there’s something we don’t under-
stand, she’s very good at explaining what’s involved, so
we’re very happy (patient)
Having a nurse, it gives you a bit more confidence because
you just know she’s there. Everyone should have one,
because it does make a heck of a difference (patient)
Box 2 Patient-carer views: draft patient-held Future Care
Plan (see appendix 2 “My Thinking Ahead Plan”)
I have thought about all the questions (in the proposed
patient-held Future Care Plan), and I think it’s very, very
good. Even for yourself to write down your thoughts and
wishes. Everybody’s wishes are different so therefore, if it’s
all written down and you’ve got this plan, I think, yes, it’s
very useful for the future (patient)
…personally, ignorance is bliss in some cases (patient)
What would worry me slightly about this, especially if
you’re filling it out on your own (Future Care Plan), is that
suddenly an end, shall we say, opens up, the fact that
you’re filling in something that’s to do with palliative care
—ooh, a horrible word—I don’t know if people with heart
failure are taken through this before this or do they need to
be sitting with a doctor or nurse who can take them
through the fact that it’s not as bad as it sounds. That
would worry me…getting something like this and filling it
in isolation, it’s frightening (patient)
Well, if you follow all the questions, really I don’t think you
miss much at all. Because you’re asking what people are
interested in and what things they do at the moment and
what they hope to continue, and in a way, I think that’s
very good for the professionals looking after us to know
that—whether in fact you’re doing anything or if you’re
doing nothing with your life, because I think it makes a big
difference (patient)
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and a value of 20% was reached as one which would
include a set of patients with a signiﬁcantly higher than
average mortality risk for cardiac patients. One further
aspect of the ﬁnal design of the trial which was discussed
and agreed by the PCFG was whether to have a control
group with no intervention or whether to have a group
of patients where an intervention was provided but
12 weeks after discharge. It was generally agreed that it
would be unethical not to provide an intervention of
some sort to all patients who agreed to take part and so
a delayed intervention group design was ﬁnally agreed
(see ﬁgure 1).
Views of HCPs
EOL care for patients with heart disease
Irrespective of role, all HCPs who were interviewed iden-
tiﬁed the issue of managing the uncertainty of prognosis
in people with advanced heart disease as a major chal-
lenge. Most agreed that prognostic uncertainty can
cause HCP to prevaricate because they are worried
about ‘getting it wrong’ (see box 3). They also expressed
concerns that discussions about EOL could remove
hope for the patient and their family.
Proposed trial of Future Care Planning
Several HCP participants drew a distinction between dif-
ferent types of patients with advanced heart disease and
wanted more clarity about what type of patient would be
eligible for the proposed trial. One cardiologist’s view
was that it would be relatively straightforward to recruit
patients with coronary disease although it would be
more complex to identify patients with heart failure
since it is hard to pinpoint at which point in their illness
trajectory they would become eligible (see box 4). For
this group, one cardiologist suggested it may be useful
to use repeated hospital admissions or functional status
as a criterion for eligibility.
Care of the elderly physicians raised concerns about
including patients in the trial with multimorbidity
including those with cognitive impairment. Such
patients are typically seen in acute medical takes and
while they would be a group who may beneﬁt consider-
ably from Future Care Planning, they would be difﬁcult
to assess, recruit and retain in the proposed trial.
However, this HCP stated that to omit these patients
would be unfair and could miss a key opportunity.
There were no signiﬁcant concerns raised with regard
to using a clinical prognostic tool, such as the GRACE
score, as a way of identifying patients for a palliative care
intervention. However, it was highlighted by a number
of HCPs that this approach has signiﬁcant limitations
and using such a tool in isolation may exclude many
patients who could beneﬁt from a Future Care Planning
approach who have a high level of need and a low esti-
mated 12-month mortality risk. In addition, it was high-
lighted that prognostic scores do not predict time to
death nor do they accurately identify those who may
beneﬁt from a palliative care intervention.
Without exception, the HCPs we interviewed had no
ethical concerns with a design utilising an early versus
late intervention which they regarded as a standard
approach for a trial (see ﬁgure 1).
Achieving and maintaining staff engagement and
thinking ahead to what happens at the end of the trial
were identiﬁed as important issues. In particular, HCPs
identiﬁed the importance of keeping staff informed
Figure 1 Adapted protocol for a randomised trial of Future Care Planning for patients with advanced heart disease: original flow
diagram did not define the types of patients to be included, the threshold mortality risk for eligibility and the control group
intervention. This final and agreed version identifies patients admitted to an acute cardiology ward with either acute coronary
syndrome or heart failure and will be screened for eligibility—12-month mortality risk of 20% or greater at the time of discharge
using the GRACE discharge score8 or the EFFECT score.7 Eligible patients need to survive to discharge and have capacity to
consent for the study. Informal carers will also participate where identified by the patient. Proposed outcomes include quality of
life assessed by questionnaire (EuroQoL-5D) and readmissions to hospital. Patients randomised to early intervention will be
interviewed prior to discharge and those randomised to delayed intervention will receive the same interview 12 weeks following
discharge. ACS, acute coronary syndrome; CHF, congestive heart failure; HF, heart failure.
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about the trial, consideration of how the trial might
dovetail with existing service developments and the
importance of providing ongoing support beyond the
trial period to participants who continue to require add-
itional supportive care.
Hospital bed-days utilisation during follow-up was gen-
erally considered to be an appropriate outcome,
although several expressed caution in interpreting what
these data actually mean. Quality of life measures were
also considered to be an appropriate outcome, although
it was pointed out that these measures can also be difﬁ-
cult to interpret in this setting. Some HCPs suggested
the inclusion of place of death and preference for place
of death as outcome measures.
The initial study design of the clinical trial did not
strictly deﬁne the types of patients that could be
included, the eligibility criteria, the threshold mortality
risk for inclusion and whether an intervention should be
included for the control group. The ﬁnal trial design
(ﬁgure 1) represents a modiﬁed version taking account
of the views of patients and HCPs interviewed in this
Box 3 Healthcare professional’s views: prognostic
uncertainty
…it’s hard for health professionals to know where they
(patients) are in their disease process, because we know
they go up and down and they probably never come right
back up to where they were the last time, but they’re still
functioning, and…at what point do you have that conversa-
tion? (District Nurse)
A lot of health professionals because of the trajectory of the
disease and the up and down nature of it, nobody knows
when the point of true palliation should kick in and people
are very frightened because with some antibiotics or some
steroids they could bounce back, not to the same state of
health, each time declining and getting less well, but still
not at the point where you would be comfortable saying,
right, we’re at the point of pure palliation (Palliative Care
Consultant)
we’ve all seen patients who survive against the odds for a
long time—if they outlive your expectations, that’s OK…
you might get the timing a bit wrong because you can’t
predict, but usually you are right that the decline has
started (Heart Failure Specialist Nurse)
You don’t want your patients to become obsessed and
totally focused on their disease—(they’ve) got to get on
with life as well (Medicine of the Elderly Consultant)
Healthcare professional’s views: risk of dying from a long-term
condition
“I don’t think they see it, to the same extent as cancer
patients—COPD patients as well. They (patients) see it as a
limiting condition, it stops them doing things, it’s not fore-
most in their mind that this is the thing they’re going to die
of” (District Nurse)
“Sometimes I think when it gets to the stage that you’re
doing DNAR forms…it often comes as a big shock to
either them or their family…it comes as a shock when
they’re told, ‘we think this is it this time’, because they’ve
been in and out, bounced back and forward, got better,
gone home” (Community Palliative Care Nurse)
Box 4 Healthcare professional’s views: proposed trial of
Future Care Planning
Patient selection for the trial:
One group is those with advanced heart failure for whom
we already have some structure to post-discharge care
through our HF nurse service and the second group…are
those with end stage coronary disease, so these are
patients with angina for whom there’s not an awful lot
more can be done for them by way of bypass surgery and
invasive treatments, and where these patients are intermit-
tently hospitalised when their angina reaches crisis point
(Consultant Cardiologist)
A score based on a patient’s functional status is useful
because it identifies when quality of life is impaired to the
extent that the patient needs more support (Consultant
Cardiologist)
Eligibility for the trial:
…harder to put frail elderly patients into a protocol-driven
trial because they are so different and they’ve got such a
mix of co-morbidities and such a mix of drugs (Consultant
in Medicine of the Elderly)
I think using (a cut-off of ) 20% (12 month mortality risk)
is fair (Community Palliative Care Nurse)
It’s still pretty high. If it’s less than 20% people shouldn’t
imminently be dying so it gives you a chance to see what
effect the intervention has (Consultant Cardiologist)
…So it’s about identifying the point when you can have a
reasonable conversation with somebody about deterior-
ation, and is 20% (estimated mortality risk) right…If you
make it higher you’ll miss some people but you’ll make the
discussion more real and liveable, and that’s your balance
(Palliative Care Consultant)
A 20% risk threshold would include lots and lots of frail
elderly people. Many of them would have a 1 in 5 chance
of dying within a year even without their heart failure. It’s
probably not an unreasonable threshold (Medicine of the
Elderly Consultant)
Trial outcome measures
…if you’re trying to prevent hospital admissions, if they’re
frequent fliers, then I would have thought they’re the ones,
the unstable ones. If you’ve been able to tweak something
at home that prevented the admission, I suppose this is
what this would do (District Nurse)
Obviously, you do have to look at bed days but ultimately
they’re spending more time in hospital, from their point of
view…that’s possibly better for them (Community Palliative
Care Nurse)
…there’s a subtle distinction, for example, between trying
to measure differences in quality of life on a day to day
basis, and measuring overall levels of comfort, security.
(Medicine of the elderly consultant)
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study. This fundamental design of the proposed trial was
similar to the original design presented to the PCFG
and the HCPs during the interviews and focus groups.
There was general agreement that a broad range of
acute cardiac patients should be included and agree-
ment was reached to include heart failure (with either
reduced or preserved left ventricular systolic function)
and patients with any ACS. There was discussion as to
whether a delayed intervention was needed in the
control group. Since current clinical services provided
little or no EOL intervention for such patients, a ﬁnal
consensus, mainly driven by comments from patients
and carers, was made to offer a delayed intervention to
the control group given that the intervention addressed
a clear need which was patient-centred and which could
provide an apparent beneﬁt to those who participated.
The ﬁnal component of the design which was agreed
following the PCFG and HCP interviews was the thresh-
old at which to set the 12-month mortality used as eligi-
bility for the trial. The authors had proposed this to be
somewhere between 20% and 40% and this was dis-
cussed by both groups. The ﬁnal agreement of 20% was
made largely by the PCFG after lengthy discussions as to
what the typical mortality risk was for patients with CCF
and ACS admitted acutely to hospital.
The ﬁndings from this modelling phase are currently
being used to support the implementation of a phase II
randomised clinical trial of a holistic intervention
(ﬁgure 2) for patients with advanced heart disease.
DISCUSSION
This qualitative study examining patients’, carers’ and
HCPs’ views on the content and design of a clinical trial
of Future Care Planning for patients with advanced
heart disease has highlighted a number of important
issues. The concerns raised by patients and carers
regarding the current inadequate levels of care as
cardiac patients approach EOL provide an important
backdrop to the main theme of the work which was to
seek their views on the content and design of a clinical
trial. Patients and carers expressed views indicating that
such a trial should redress the current inadequacies in a
typical doctor–patient interaction which they felt had
limited time and lacked a holistic approach particularly
in cardiology outpatient clinic settings. The HCP partici-
pants highlighted the challenges in using meaningful
selection criteria for the trial and the complexity of
identifying precisely which component of any proposed
intervention might inﬂuence outcomes. The ﬁndings of
this work therefore reafﬁrm many of the ﬁndings of
others in the ﬁeld.18 19 However, the novel aspect of the
work is that the focus groups and interviews were
extended beyond a general discussion stage to seek
views on how the inadequacies in care could be
redressed and a model developed which could be subse-
quently tested using a randomised trial approach.
Factors which might inﬂuence the outcomes which
emerged from the PCFG discussions included the
content and quality of the baseline or ﬁrst discussion/
interview with the consultant, the content of the written
FCP and ongoing support, for patient and carer, from a
familiar HCP. The views from patients, carers and profes-
sionals indicated that a clinical trial should focus on pro-
viding adequate time to discuss the patient’s current and
future care needs and those of their carer, it should
select patients on the basis of prognosis and needs, it
should provide ongoing support with primary and sec-
ondary care working closely together to ensure good
coordination of care and it should allow for adaptation
of any care plan in a dynamic way that is aligned with
the changing needs of the patients and their carers.
While this message is clear, delivering such a trial using
non-palliative care physicians in an acute cardiology
environment will be challenging. Finding the appropriate
language to explain an uncertain prognosis is always difﬁ-
cult,20 and cardiologists with a ﬁrm culture of curative
approaches may struggle to ﬁnd that language. These
challenges may delay the conversation until it is too late,
or they may encourage the use of more vague, ambiguous
or even contradictory language which can sometimes
mislead the patient and their family or fail to communi-
cate the seriousness of their condition adequately.
Finding language that is balanced, caring and which
makes sense of an uncertain future is one of the chal-
lenges of all palliative care even where the prognosis,
good or bad, is more certain. However, the majority of
the HCPs who we interviewed agreed that it should be
possible in most cardiac patients with advanced disease.
Surviving with a chronic condition that has an uncertain
illness trajectory can mean that these patients, unlike
patients with cancer, can reach a fairly advanced stage in
their illness without realising that they have a condition
that could and probably will cause their death.
Our ﬁndings have also highlighted a persisting ten-
dency for patients and HCPs to associate palliative care
with dying. This perception may prevent or discourage
healthcare teams from offering palliative and supportive
care to patients with signiﬁcant symptom burden who
may not have reached the end of their lives but who
may beneﬁt form additional supportive care. HCPs held
the view that patients and carers may be reluctant to
accept a form of support which they associate with EOL.
This may reﬂect reluctance on the part of the HCPs as
much as the patient. This is an important issue if we are
to develop a model of integrating palliative care earlier
in the illness trajectory of cardiac disease by the heart
team caring for the patient. In addition to learning and
developing the skills required to do this, these teams will
also need to change attitudes and culture. Indeed, while
this culture is increasingly acknowledged as important
for patients with chronic heart failure, there is also a
clear need for this approach in patients with other
forms of advanced cardiac disease such as coronary and
valvular heart disease.
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The barriers to achieve good holistic care for patients
nearing the end of their lives, well described in other set-
tings,21 22 apply equally well in the acute cardiology
setting.23 There is insufﬁcient time to discuss such sensi-
tive issues, the hospital environment is not ideal (particu-
larly in multi-bedded rooms), cardiologists are not
adequately trained and in cardiology there is a culture of
doing more and never giving up. However, particularly in
elderly patients and even with optimal interventions, the
combination of CHF, coronary heart disease, valvular
heart disease and other non-cardiac comorbidities is asso-
ciated with poor prognosis.24 25 Indeed, the increasing
Figure 2 Future Care Plan (FCP) intervention: the intervention will last for 12 weeks. Patients randomised to early intervention
will have a 1 h interview with a cardiologist prior to discharge where they will discuss their heart condition, other medical
conditions and their concerns and plans for the future. The cardiologist, trained in Advanced Communication Skills, will aim to
address a range of issues including (1) a FCP, agreed with the patient and their carer, which includes advice to healthcare
professionals about what could and should be done if the patient’s condition deteriorates once again, (2) whether the patient and
their family have arranged Power of Attorney (or similar), (3) whether the patient wishes to consider the issue of DNACPR (Do
Not Attempt Cardiopulmonary Resuscitation), (4) whether the patient wishes to express a preferred place of care should their
condition deteriorate again, (5) whether the patient would consider being added to their general practitioner’s (GP) Palliative Care
register and (6) permission to share the content of the FCP electronically with out-of-hours medical services (NHS24/NHS
Direct). Patients will also be encouraged to complete ‘Thinking Ahead Plan’, a locally developed patient-held anticipatory care
plan (see online supplementary appendix 2). Patients randomised to delayed intervention will undergo the same interview
12 weeks after discharge. During the follow-up period of 12 weeks, the trial nurse will visit the patients/carers in their home at 6
and 12 weeks after the baseline interview in order to update the FCP with any changes and to review any DNACPR orders or
make any necessary changes to the plan of care. An updated version of the FCP record will be communicated in writing to the
GP at each of these time points. The nurse will be available to communicate with the patient by telephone at any time and will
ensure optimal communication and coordination of care between GP, cardiologist, community-based nursing teams and palliative
care teams (where appropriate).
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use of transcatheter aortic valve implantation in patients
who are deemed unsuitable for conventional surgery is
increasingly recognised as a clinical challenge balancing
aggressive intervention with supportive EOL care.26–29
Hence, patients with advanced heart disease and poor
prognosis are clearly a target for better clinical care
encompassing an approach that acknowledges that the
patient may be nearing the EOL. These patients rarely
receive care that addresses their individual needs and
those of their informal carers. This care need not be
labelled as palliative but can be delivered in the under-
standing that the future is uncertain and the risk of
death, either sudden or with progressive symptoms, is
signiﬁcantly increased. This need not exclude a positive
attitude to the patient’s clinical care and where possible
the HCP should emphasise the need for ongoing active
and responsive care. The challenge, and arguably the
key issue, is maintaining a positive attitude while simul-
taneously acknowledging a poor prognosis. However, if
this approach can be adopted by the patients, their
family, general practitioner and cardiologist, then it can
potentially improve communication and understanding
in a way that leads to better care without loss of hope for
the patient. Any such intervention should be patient-
centred in all aspects of its design and the impact on
healthcare measures must be seen as secondary to the
primary aim of improving quality of life. This is challen-
ging even in cancer care where there have been few clin-
ical trials adequately powered to show clinically
meaningful beneﬁts using a holistic approach.12 If
improved clinical outcomes could be demonstrated in a
clinical trial involving patients with advanced heart
disease, then this would be extremely valuable to
patients and the wider cardiology community.
This study has clearly demonstrated that patients,
carers and HCPs have a number of concerns in relation
to providing high-quality holistic care for patients with
advanced heart disease. The approach reported here of
seeking views on the inadequacies in service provision,
designing an intervention model that could improve
care and incorporating this into the design of a rando-
mised trial is novel and important given the dearth of
clinical trials in EOL care. The ﬁndings are currently
being used to support implementation of a phase II ran-
domised clinical trial of a holistic intervention involving
Future Care Planning for patients with advanced heart
disease.
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